Press Releases

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks Leave a reply REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline Natural history analysis showed that 87% of untreated FAP patients – who resembled the inclusion criteria of TUPELO – had annualized polyp-burden increase, 10% remained stable, and 3% showed modest decrease—underscoring the disease’s progressive trajectory (n=55) 40% of patients (4 out of 10) achieved a ≥1-point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management REC-4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment-related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety-evaluable patients, and no Grade ≥4 TRAEs reported to date First clinical validation of the Recursion OS, demonstrating how unbiased phenotypic and mechanistic insights—such as MEK1/2 rescue of APC loss-of-function—can translate to novel, differentiated therapeutics for diseases like FAP with no approved therapy and high prevalence of >50,000 patients in US and EU5 Next steps: Engage the FDA in the 1H26 to define a potential registration pathway, and in parallel, expand the population from ≥55 to ≥18 years old, and further optimize dosing schedule SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across digital asset markets. The fund peaked at $811,031,000 on October 6 and registered a monthly low of $691,886,000 on October 17, maintaining stability even as broader crypto prices declined. October marked one of the more turbulent months for the industry this year, with major assets facing sharp corrections and heightened volatility. Against this backdrop, Bitget’s Protection Fund, established in 2022 with a base commitment of $300 million, continued to demonstrate resilience and transparency. The fund’s October average remains nearly 147% above its original allocation, reaffirming the UEX’s capacity to safeguard user assets even in unpredictable conditions. Bitget October 2025 Protection Fund Overview Bitget October 2025 Protection Fund Overview The Protection Fund provides an independently verifiable safety net designed to protect users during abnormal market events. Valuations are updated daily based on prevailing market conditions and asset holdings, ensuring full visibility into available coverage at any point in time. Alongside the Protection Fund, Bitget’s Proof of Reserves (PoR) maintains a 1:1 reserve ratio or higher for all user assets. Together, the initiatives form a comprehensive protection framework with the PoR ensuring complete backing, while the Protection Fund offers an additional layer of defense during periods of extreme volatility. “As we advance toward a borderless Universal Exchange, security and transparency must lead the way. A sustained Protection Fund above $700 million and being transparent in our Protection Fund numbers every month builds trust for users to engage with the market confidently, even in volatile conditions,” said Gracy

EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group Christopher Potts, Chief Operating Officer & Chief Technology Officer, EBC Financial Group (UK) Ltd, representing EBC Financial Group to receive the Best Broker for Execution at the Professional Trader Awards 2025 by Holiston Media. LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for Execution at the Professional Trader Awards 2025, organised by Holiston Media. Now in its sixth year, the programme recognises excellence across 16 categories, with winners determined through a mix of nominations and trader voting. “At the heart of EBC are trust and respect—values that translate into delivering exceptional service that respects the trade,” said David Barrett, CEO of EBC Financial Group (UK) Ltd. “For professional traders, execution is not just a feature; it is mission-critical. It shapes every aspect of a workflow, from decision-making to risk calibration. This award validates our investment in the infrastructure necessary to create the best possible trading environment.” High Engagement Reflects Evolving Trader Priorities Launched initially to spotlight brokers offering professional client accounts, the Professional Trader Awards have expanded to recognise the wider active trading community. Brokers participate in the awards process, and winners are determined by votes from professional, active or prop traders. Barrett stated, “The voting process demonstrates which service elements traders themselves view as essential. It provides clear insight into how brokers are meeting the operational standards expected by experienced traders.” He added that for EBC Financial Group, being evaluated directly by market participants highlights the firm’s alignment with the high standards required by

Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship rights. New client data released today by global leaders in citizenship and residence planning, Henley & Partners, confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term destination decisions for globally mobile families. Record Global Demand is Reshaping Priorities Henley & Partners has received applications from 92 nationalities this year (2025) and supported demand across 50+ residence and citizenship programs. Over the past five years, the firm has assisted applicants from 136 nationalities, underscoring the scale and diversity of today’s wealth-migration movement. Comparing the first three quarters of 2024 with the same period in 2025, the firm has seen a 43% increase in applications — a clear signal of intensifying cross-border mobility among affluent families. “Global mobility is becoming a core risk-management strategy for wealthy families,” according to Dr. Christian H. Kaelin, Chairman of Henley & Partners. “As clients build lives across multiple jurisdictions, they are scrutinizing not only access to residence and citizenship, but also the real cost of sustaining that lifestyle — especially the price of reliable private healthcare. Destinations that look attractive on paper can become far less so once true healthcare exposure is understood.” New Evidence Turns Healthcare Costs into a Core Mobility Metric To support clients’ destination decisions, Henley & Partners is referencing the newly published SIP Health Cost Index (HCI) 2025 — a systematic benchmark of the true cost of private healthcare for internationally mobile individuals and families